Merck Drops India From Main-Markets List, But Keeps Brazil, China, Russia
This article was originally published in PharmAsia News
Merck no longer considers India one of its priority markets when it comes to its global initiative that focuses on Brazil, China and Russia instead.
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.